Cocoburra Cosmeceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.75 M
as on 03-07-2024
- Paid Up Capital ₹ 0.13 M
as on 03-07-2024
- Company Age 5 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 195.17%
(FY 2023)
- Profit -176.55%
(FY 2023)
- Ebitda -192.93%
(FY 2023)
- Net Worth 60.72%
(FY 2023)
- Total Assets 107.63%
(FY 2023)
About Cocoburra Cosmeceuticals
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.75 M and a paid-up capital of Rs 0.13 M, as per Ministry of Corporate Affairs (MCA) records.
Vidhi Vachharajani, Kaushik Dutta, and Kasturi Sen serve as directors at the Company.
- CIN/LLPIN
U24304MH2019PTC326374
- Company No.
326374
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jun 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Cocoburra Cosmeceuticals Private Limited offer?
Cocoburra Cosmeceuticals Private Limited offers a wide range of products and services, including Cosmetics Beauty, Propyl Paraben Sodium, Me Pharm, Acetyl Ethylene Urea, Mosquito Repellant, Mosquito Repellent Cream, Medicines, Benzoyl Peroxide, Benzoyl Peroxide Chemical, Medical Treatments.
Who are the key members and board of directors at Cocoburra Cosmeceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kaushik Dutta  | Director | 24-May-2022 | Current |
| Kasturi Sen | Director | 06-Jun-2019 | Current |
| Vidhi Vachharajani | Director | 06-Jun-2019 | Current |
Financial Performance of Cocoburra Cosmeceuticals.
Cocoburra Cosmeceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 195.17% increase. The company also saw a substantial fall in profitability, with a 176.55% decrease in profit. The company's net worth Soared by an impressive increase of 60.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cocoburra Cosmeceuticals?
In 2023, Cocoburra Cosmeceuticals had a promoter holding of 88.56% and a public holding of 11.44%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cocoburra Cosmeceuticals?
Unlock and access historical data on people associated with Cocoburra Cosmeceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cocoburra Cosmeceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cocoburra Cosmeceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
